pragma.vision Technology observatory & strategic foresight

Verification register Bio, Health & Neuro

Readiness verdict

OpenCRISPR-1

A dated reading of what is claimed, reported, and independently verified in the current evidence.

As of
2026-08-20
Revision
1
Method
v1.3.0

Current reading

Readiness band and full integer triple

AI-assisted assembly · derived results

Readiness band

Ready

Primary summary from verified readiness

Confidence
79% · stale
Computed at
2026-08-20T10:54:19.730593+00:00
Claimed
70

Public ambition and stated capability

Reported
70

Observed practitioner reporting

Verified
64

Independently supported evidence

Gap
+6

Claimed leads verified

Evidence strength Strong

Decision

What the current evidence supports

Human editorial judgment · 2026-08-20

Adopt with guardrails

Why
Nature-published (2025-07-30), openly available, with measured on-target parity (55.7% vs 48.3% median indel) and ~95% lower off-target editing (0.32% vs 6.1%) whose off-targets are a subset of SpCas9's with no new edits — strong for research adoption; the guardrails are licensing and the absence of in vivo therapeutic validation.
Next
Use the open GitHub/AddGene sequence for in vitro / research editing where higher specificity matters; benchmark against SpCas9 on your loci. For any commercial/therapeutic path, execute the Profluent license and run full biosafety evaluation first.

Constraints

Blockers

No named blocker is present in the current public projection.

Evidence summary

Derived counts

AI-assisted assembly

Total
11
Tier 1
0
Tier 2
8
Tier 3
3
Supports
8
Contradicts
2
Context
1
Latest observed
2026-01-01

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Revisions

Initial public reading

  1. 2026-07-19 Reading moved from ready to ready.

Your opinion

Tell us anything.

What works, what doesn't, what's missing — especially about our watches, lenses, and the register itself. Anonymous is fine; leave an email if you'd like a reply.